BioPlayground

PC

ProtocolCore

Suggested Protocols

탐색형 MVP
전체 프로토콜 분야

Protein & Antibody Workflows — Recombinant Production

하나의 입구에서 제품을 정의하고, 서로 다른 생산 route를 선택

단백질·항체 이름마다 protocol을 늘리지 않습니다. 공통 Product Definition 뒤 BL21/T7, HEK293 transient, CHO transient, CHO stable pool, CHO clonal producer 중 하나를 선택하고 선택한 route의 source와 인계 계약만 export합니다.

편집 가능한 시작 프로토콜

5 bounded routes

이 프로토콜은 무엇을 하나요?

제품 정의를 먼저 고정한 뒤 미생물 또는 포유류 생산 route 하나만 선택하고, 선택한 source의 배양·발현·회수·정제·QC 단계를 연결합니다.

지원하는 생산 route

  • • G. Recombinant expression, production & purification

적용 경계

HEK와 CHO, transient와 stable pool·clone 조건은 서로 공유하지 않습니다. 선택하지 않은 host의 조건을 추천하거나 export하지 않습니다.

Protein Production 저장 상태를 확인하고 있습니다.

연구용 기록(RUO)이며 출하 승인 또는 규제 lot release가 아닙니다.

PRT-PROTEIN-PRODUCTION-P1D-001G. Recombinant expression, production & purification

Source-Governed Recombinant Protein Production Composer

Protein & Antibody Workflows > Recombinant Protein Expression, Production & Purification · PRT-PROTEIN-PRODUCTION-P1D-CENSUS-20260828

공식 가이드 검토됨
ONE_CATALOG_ENTRY_FIVE_BOUNDED_ROUTESBL21_HEK_CHO_CONDITIONS_NEVER_SHAREDTRANSIENT_POOL_CLONE_TERMINAL_STATES_DISTINCTEXACT_HOST_DERIVATIVE_AND_SOURCE_REQUIREDFIVE_SOURCE_BLOCKS_REQUIREDSOURCE_GOVERNED_COMPOSEDCONNECT_HANDOFF_CONTRACT_REQUIREDADD_REMOVE_REPLACE_FOR_PERSONALIZATIONNO_UNIVERSAL_NUMERIC_DEFAULTSRESEARCH_USE_ONLY

PROTEIN PRODUCTION FOUNDATION

목적과 범위

연구용 recombinant protein 생산을 위한 workflow composer입니다. 제품·construct·host를 먼저 기록하고, host biology와 expression mode가 다른 다섯 route를 분리합니다. GMP, 임상·진단 적합성, release 또는 biosafety 등급을 인증하지 않습니다.

시작 전에 반드시 정의할 것

  • 제품 identity·목적·format·subunit
  • sequence/construct version과 tag·signal·marker
  • 필요한 folding·PTM/glycan·assembly·activity
  • 목표 scale/context와 downstream use
  • exact host derivative·stock/bank와 medium/system

실행 전 확인

  • host 이름이 아니라 exact derivative와 source를 확인
  • host·expression·recovery·purification·quality source snapshot을 각각 기록
  • route 사이 숫자와 조건을 carry-over하지 않음
  • manufacturer step 변경은 ADD/REMOVE/REPLACE와 qualification 기록
  • stop/route-out 및 terminal state를 실험 전에 정의

내부 route map

BL21, HEK, CHO를 카드 수백 개로 만들지 않고 한 composer 안의 bounded route로 둡니다. CHO stable pool과 clonal producer도 terminal state가 달라 분리합니다.

BL21(DE3) 계열 T7 미생물 발현

Transformation/selection, source-qualified seed, small expression screen, induction, total·soluble·localized 판정 뒤 scale 또는 route-out합니다.

Product/construct definitionExact strain/vector qualificationTransformation and selectionSource-qualified seedSmall expression screenInduction strategyTotal/soluble/localized assessmentScale or route-outHarvest/recoveryPurification/QC handoff

Terminal: Assessed microbial harvest fraction with total/soluble/insoluble or localized-state provenance

HEK293 계열 transient 발현

정확한 HEK293 derivative와 adherent/suspension platform, transfection system, expression/viability, secreted/intracellular harvest를 기록합니다.

Product/construct definitionExact HEK derivative/platform qualificationMaintenance/seed readinessTransfection readinessConstruct deliveryExpression/viability monitoringSecreted or intracellular harvestClarificationPurification/QC handoff

Terminal: Assessed HEK293-derived transient harvest with cell/platform and batch provenance

CHO 계열 transient 발현

정확한 CHO derivative와 CHO-specific transfection/protocol variant를 사용하며 HEK 조건을 가져오지 않습니다.

Product/construct definitionExact CHO derivative/platform qualificationMaintenance/seed readinessCHO transfection readinessConstruct delivery and protocol variantExpression/viability monitoringHarvestClarificationPurification/QC handoff

Terminal: Assessed CHO-derived transient harvest with exact protocol-variant and batch provenance

CHO stable pool 개발

Integration/transfection, selection, pool recovery, productivity·product-quality·stability를 지나 qualified stable population에서 끝납니다.

Product/construct definitionExact CHO platformTransfection/integrationSelectionStable-pool recoveryPool productivity/product-quality screenStability assessmentQualified poolProduction harvestPurification/QC handoff

Terminal: Qualified CHO stable pool with selection, productivity, product-quality, and stability provenance

CHO clonal producer 개발

Stable pool 뒤 single-cell provenance, clone screening, stability와 bank를 추가하며 clonality를 추정하지 않습니다.

Product/construct definitionExact CHO platformTransfection/integrationSelection and pool recoverySingle-cell isolation/provenanceClone screeningProductivity/product-quality/stabilityQualified bankProduction harvestPurification/QC handoff

Terminal: Qualified CHO clonal producer bank with single-cell provenance, clone selection, stability, and bank record

공통 decision / stop

  • 제품 요구와 host/route가 맞지 않으면 보류
  • starting culture가 source readiness를 못 채우면 중지
  • 발현·solubility·viability·stability·clonality 증거가 부족하면 route-out
  • recovery output과 purification input이 맞지 않으면 CONNECT 실패
  • QC는 fit-for-purpose이며 자동 release가 아님

최종 인계

선택 route, exact sources, batch/fraction/QC provenance, 모든 CONNECT, change ledger, terminal state, storage와 unresolved risk를 남깁니다. Export에는 선택하지 않은 host의 조건이 포함되지 않습니다.

Reference 사용 원칙

본문은 기본 workflow를 직접 설명합니다. 실제 숫자·reagent·medium·시간·온도·선택압·harvest·resin 조건은 사용자가 선택한 exact 제조사 문서와 revision이 지배합니다. 논문은 구조와 분기 근거이며 자동 recipe가 아닙니다.

ADD / REMOVE / REPLACE

제조사 protocol을 그대로 채택하더라도 exact 제품·catalog·lot/bank·문서 revision·locator를 기록하세요. 단계나 조건을 추가·삭제·대체하면 ADD / REMOVE / REPLACE, 이유, local qualification과 rollback을 반드시 남겨야 합니다.

Research Use Only · no GMP, release, clinical/diagnostic-fitness, or biosafety-class claim.

먼저 내 assay 정보를 채워 주세요

실행 순서와 합리적인 시작 조건을 정리한 초안입니다. 샘플 primer·probe 서열은 넣지 않았습니다. 반드시 자신의 표적 서열을 입력하고, 실제 효소·kit·장비 설명서와 assay 검증 결과에 맞게 조건을 확정하세요.

1

0. DEFINE THE PRODUCT AND INTENDED USE

Record protein or antibody identity, research purpose, format/subunits, sequence and construct version, expected localization, folding/PTM/assembly/activity needs, target scale, downstream use, and fit-for-purpose quality context before selecting a host.

조건: No universal best host is assigned. Unresolved product attributes remain explicit routing questions.
2

1. SELECT ONE BOUNDED PRODUCTION ROUTE

Choose BL21/T7, HEK293 transient, CHO transient, CHO stable pool, or CHO clonal producer. Record the exact strain/cell derivative and expression mode; do not create a protocol card for each protein, antibody, or host record.

조건: Changing route resets route-specific sources, handoffs, and decisions so conditions cannot leak across hosts.
3

2. FREEZE CONSTRUCT AND HOST-SYSTEM RECORDS

Link the product definition to one exact expression construct and one exact host/stock/bank record. Capture vector/promoter, signal/localization elements, tags, markers, multi-chain pairing, host origin, derivative, source, lot/bank/passage context, medium/system, and change history.

시약: USER REQUIRED — exact construct and host-system records조건: HEK293 derivatives and CHO derivatives are not synonyms; BL21(DE3) is not equivalent to non-DE3 or non-T7 microbial systems.
4

3. QUALIFY THE ROUTE-SPECIFIC STARTING CULTURE

Follow the exact host-system source for transformation/selection and seed preparation in the microbial route, or maintenance/seed readiness in mammalian routes. Stable routes additionally require an integration/selection plan and defined population endpoint.

조건: Record actual readiness evidence and route out when the exact source requirements are not met.
5

4. EXECUTE THE SELECTED EXPRESSION OR DEVELOPMENT ROUTE

Apply only the selected route state machine: small-screen and induction for BL21/T7; transient transfection and monitoring for HEK293 or CHO; integration, selection, pool recovery, and optional clonal development only in the corresponding stable route.

시약: USER REQUIRED — exact expression/transfection/integration/selection source snapshot조건: All manufacturer additions, removals, or replacements are explicit. The scaler performs arithmetic only from user-entered source values and recommends no reagent or condition.
6

5. PASS ROUTE-SPECIFIC DECISION AND STOP POINTS

Assess total versus soluble/localized expression for BL21, cell/platform readiness and harvest criteria for transient mammalian routes, stable-population qualification for stable pools, and single-cell provenance plus stability/banking evidence for clonal producers.

조건: Low expression, incompatible quality, failed recovery, unsupported clonality, or source mismatch causes hold or route-out rather than an automatic PASS.
7

6. HARVEST, RECOVER, AND PRESERVE FRACTION PROVENANCE

Record harvest criterion, localization, starting matrix, clarification or lysis/refolding/membrane operation, retained and discarded fractions, volume/concentration basis, deviations, and the exact material state handed to purification.

조건: Secreted supernatant, intracellular soluble fraction, inclusion body, periplasmic and membrane fraction are different inputs and never share a hidden recovery recipe.
8

7. DESIGN AND EXECUTE THE SOURCE-GOVERNED PURIFICATION TRAIN

Choose capture, intermediate, and polishing operations only when required by the product and supported by exact product/resin/membrane/equipment IFUs. Record the fraction ledger and every source-to-source CONNECT contract.

시약: USER REQUIRED — exact purification product and IFU snapshots조건: A general handbook does not authorize resin-specific capacity, flow, buffer, pressure, cleaning, or lifetime values.
9

8. COMPLETE FIT-FOR-PURPOSE PRODUCT QC

Record method and result provenance for quantity, identity, purity/aggregate, activity, product-specific PTM/assembly, process/product impurities and endotoxin context where relevant. Define acceptance in relation to the stated research use.

조건: The composer does not infer release criteria, potency, GMP readiness, clinical suitability, or manufacturing consistency.
10

9. CLOSE THE ROUTE-SPECIFIC HANDOFF

Export only the selected route, exact source snapshots, CONNECT reviews, change ledger, batch/fraction/QC records, terminal state, storage, and downstream handoff. Keep unresolved risks and route-outs visible.

조건: Output is Research Use Only. Stable pool and clonal producer bank remain distinct terminal states.